David F. Carroll

Chief Financial Officer & Treasurer at Ophthotech Corp.

David F. Carroll

David F. Carroll

Chief Financial Officer & Treasurer at Ophthotech Corp.

Biography

David F. Carroll occupies the position of CFO, Treasurer, Principal Accounting Officer & SVP at Ophthotech Corp. In his past career Mr. Carroll was Chief Accounting Officer & Senior Vice President for The Medicines Co. Mr. Carroll received an undergraduate degree from Ursinus College and an MBA from Rutgers State University of New Jersey.

Overview
Career Highlights

Ophthotech Corp.

RelSci Relationships

224

Birthday

1966

Age

53

Relationships
RelSci Relationships are individuals David F. Carroll likely has professional access to. A relationship does not necessarily indicate a personal connection.

President, Chief Executive Officer & Director at Ophthotech Corp.

Relationship likelihood: Strong

Co-Founder at Imagen Biotech, Inc.

Relationship likelihood: Strong

Managing Partner NOVO Ventures at Novo Holding A/S

Relationship likelihood: Strong

Co-Founder & Chief Executive Officer at Inozyme Pharma, Inc.

Relationship likelihood: Strong

Director at Ophthotech Corp.

Relationship likelihood: Strong

Co-Founder at Clarus Ventures LLC

Relationship likelihood: Strong

Former President & Chief Executive Officer at Alba Therapeutics Corp.

Relationship likelihood: Strong

Senior Vice President & Chief Operating Officer at Ophthotech Corp.

Relationship likelihood: Strong

Vice President, Regulatory Affairs at Agilis Biotherapeutics, Inc.

Relationship likelihood: Strong

Vice President, General Counsel & Corporate Secretary at Ophthotech Corp.

Relationship likelihood: Strong

Paths to David F. Carroll
Potential Connections via
Relationship Science
You
David F. Carroll
Chief Financial Officer & Treasurer at Ophthotech Corp.
Education

Rutgers, The State University of New Jersey, is a leading national research university and the state’s preeminent, comprehensive public institution of higher education. Rutgers is dedicated to teaching that meets the highest standards of excellence; to conducting research that breaks new ground; and to providing services, solutions, and clinical care that help individuals and the local, national, and global communities where they live. Founded in 1766, Rutgers teaches across the full educational spectrum: preschool to precollege; undergraduate to graduate; postdoctoral fellowships to residencies; and continuing education for professional and personal advancement.

"Ursinus is a remarkable college--student centered, academically rigorous, ambitious, achieving, serious about students in the community--focused, in other words, on the right things."

Career History
Chief Financial Officer & Treasurer
2016 - Current

Ophthotech Corp. is a biopharmaceutical company,which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.

Chief Accounting Officer & Senior Vice President
2008 - 2016

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Public Holdings
Restricted data only for RelSci Professional users.
Other Affiliations

David F. Carroll is affiliated with Ophthotech Corp., The Medicines Co.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by David F. Carroll. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of David F. Carroll's profile does not indicate a business or promotional relationship of any kind between RelSci and David F. Carroll.